Aug 2026
Targeting PKM2 by (+)-homocrepidine A restrains glycolytic reprogramming and reshapes macrophage fate to alleviate acute lung injury.
HCA is identified as the bioactive enantiomer responsible for the anti-ALI activity of HCA and PKM2-mediated immunometabolic reprogramming underlies its protective effects, establishing PKM2 as a promising therapeutic target and (+)-HCA as a potential lead compound for ALI treatment.
Rong-Rong Dong, Yu Yang, Na Luo et al.
· Biochemical Pharmacology · 0 citations